Drug delivery/imaging multifunctionality of mesoporous silica-based composite nanostructures

Expert Opinion on Drug Delivery

Volumn 11, Issue 6, 2014, Pages 917-930

  Chen, Yu ^a   Chen, Hangrong ^a   Shi, Jianlin ^a  

^a SHANGHAI INSTITUTE OF CERAMICS   (China)

Author keywords

Cancer; Drug delivery; Mesoporous silica; Nanomedicine; Theranostic

Indexed keywords

ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; DOXORUBICIN; MESOPOROUS SILICA NANOPARTICLE; NANOPARTICLE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

BIOCOMPATIBILITY; BIOLOGICAL ACTIVITY; BIOSAFETY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MEDICAL TECHNOLOGY; MULTIDRUG RESISTANCE; NANOBIOTECHNOLOGY; NANOFABRICATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; REVIEW; SYNTHESIS;

CANCER; DRUG DELIVERY; MESOPOROUS SILICA; NANOMEDICINE; THERANOSTIC;

ANIMALS; ANTINEOPLASTIC AGENTS; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NANOSTRUCTURES; NEOPLASMS; POROSITY; SILICON DIOXIDE;

EID: 84901270880     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.908181     Document Type: Review

References (104)

1. Vallet-Regi M, Ramila A, del Real RP, et al. A new property of MCM-41: Drug delivery system. Chem Mater 2001;13:308-11 (Pubitemid 32199334
2. Chen Y, Chen HR, Shi JL. In vivo bio-safety evaluations and diagnostic/ therapeutic applications of chemically designed mesoporous silica nanoparticles. Adv Mater 2013;25:3144-76
3. Yang PP, Gai SL, Lin J. Functionalized mesoporous silica materials for controlled drug delivery. Chem Soc Rev 2012;41:3679-98
4. Lin YS, Hurley KR, Haynes CL. Critical considerations in the biomedical use of mesoporous silica nanoparticles. J Phys Chem Lett 2012;3:364-74
5. Shi JL, Chen Y, Chen HR. Progress on the multifunctional mesoporous silica-based nanotheranostics. J Inorg Mater 2013;28:1-11
6. Vallet-Regi M, Balas F, Arcos D. Mesoporous materials for drug delivery. Angew Chem Int Ed 2007;46:7548-58 (Pubitemid 47556998
7. Mamaeva V, Sahlgren C, Linden M. Mesoporous silica nanoparticles in medicine-Recent advances. Adn Drug Deliv Rev 2013;65:689-702
8. Lu J, Liong M, Li ZX, et al. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small 2010;6:1794-805
9. Liu TL, Li LL, Teng X, et al. Single and repeated dose toxicity of mesoporous hollow silica nanoparticles in intravenously exposed mice. Biomaterials 2011;32:1657-68
10. He QJ, Zhang ZW, Gao F, et al. In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: Effects of particle size and PEGylation. Small 2011;7:271-80
11. Chen Y, Chen HR, Guo LM, et al. Hollow/rattle-Type mesoporous nanostructures by a structural difference-based selective etching strategy. ACS Nano 2010;4:529-39
12. Chen Y, Chen HR, Ma M, et al. Double mesoporous silica shelled spherical/ ellipsoidal nanostructures: Synthesis and hydrophilic/hydrophobic anticancer drug delivery. J Mater Chem 2011;21:5290-8
13. Chen AM, Zhang M, Wei DG, et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009;5:2673-7
14. Slowing II, Trewyn BG, Giri S, et al. Mesoporous silica nanoparticles for drug delivery and biosensing applications. Adv Funct Mater 2007;17:1225-36 (Pubitemid 46847636
15. Chen Y, Chen HR, Zeng DP, et al. Core/shell structured hollow mesoporous nanocapsules: A potential platform for simultaneous cell imaging and anticancer drug delivery. ACS Nano 2010;4:6001-13
16. Liong M, France B, Bradley KA, et al. Antimicrobial activity of silver nanocrystals encapsulated in mesoporous silica nanoparticles. Adv Mater 2009;21:1684-9
17. Zhu M, Wang HX, Liu JY, et al. A mesoporous silica nanoparticulate/beta- TCP/BG composite drug delivery system for osteoarticular tuberculosis therapy. Biomaterials 2011;32:1986-95
18. Yamada H, Urata C, Aoyama Y, et al. Preparation of colloidal mesoporous silica nanoparticles with different diameters and their unique degradation behavior in static aqueous systems. Chem Mater 2012;24:1462-71
19. He QJ, Shi JL, Zhu M, et al. The three-stage in vitro degradation behavior of mesoporous silica in simulated body fluid. Micropor Mesopor Mater 2010;131:314-20
20. Cauda V, Schlossbauer A, Bein T. Bio-degradation study of colloidal mesoporous silica nanoparticles: Effect of surface functionalization with organo-silanes and poly(ethylene glycol). Micropor Mesopor Mater 2010;132:60-71
21. Hudson SP, Padera RF, Langer R, et al. The biocompatibility of mesoporous silicates. Biomaterials 2008;29:4045-55
22. Huang XL, Zhuang J, Teng X, et al. The promotion of human malignant melanoma growth by mesoporous silica nanoparticles through decreased reactive oxygen species. Biomaterials 2010;31:6142-53
23. Slowing II, Vivero-Escoto JL, Trewyn BG, et al. Mesoporous silica nanoparticles: Structural design and applications. J Mater Chem 2010;20:7924-37
24. Torney F, Trewyn BG, Lin VSY, et al. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Nat Nanotechnol 2007;2:295-300
25. Rosenholm JM, Sahlgren C, Linden M. Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles - opportunities & challenges. Nanoscale 2010;2:1870-83
26. Tang FQ, Li LL, Chen D. Mesoporous silica nanoparticles: Synthesis, biocompatibility and drug delivery. Adv Mater 2012;24:1504-34
27. Kobler J, Moller K, Bein T. Colloidal suspensions of functionalized mesoporous silica nanoparticles. ACS Nano 2008;2:791-9
28. Chen Y, Xu P, Chen H, et al. Colloidal HPMO nanoparticles: Silica-etching chemistry tailoring, topological transformation, and nano-biomedical applications. Adv Mater 2013;25:3100-5
29. Chen Y, Chen H-R, Shi J-L. Construction of homogenous/ heterogeneous hollow mesoporous silica nanostructures by silica-etching chemistry: Principles, synthesis, and applications. Acc Chem Res 2014;47:125-37
30. Pan LM, He QJ, Liu JN, et al. Nuclear-Targeted drug delivery of TAT. peptide-conjugated monodisperse mesoporous silica nanoparticles. J Am Chem Soc 2012;134:5722-5
31. Pan LM, Liu JA, He QJ, et al. Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles. Biomaterials 2013;34:2719-30
32. Zhao YN, Vivero-Escoto JL, Slowing II, et al. Capped mesoporous silica nanoparticles as stimuli-responsive controlled release systems for intracellular drug/gene delivery. Expert Opin Drug Deliv 2010;7:1013-29
33. Li ZX, Barnes JC, Bosoy A, et al. Mesoporous silica nanoparticles in biomedical applications. Chem Soc Rev 2012;41:2590-605
34. Meng HA, Liong M, Xia TA, et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010;4:4539-50
35. Torney F, Trewyn BG, Lin VSY, et al. Mesoporous silica nanoparticles deliver DNA and chemicals into plants. Nat Nanotechnol 2007;2:295-300 (Pubitemid 46882970
36. Xia TA, Kovochich M, Liong M, et al. Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano 2009;3:3273-86
37. He QJ, Zhang JM, Shi JL, et al. The effect of PEGylation of mesoporous silica nanoparticles on nonspecific binding of serum proteins and cellular responses. Biomaterials 2010;31:1085-92
38. Zhou JH, Rossi JJ. Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides 2011;21:1-10
39. Patra CR, Bhattacharya R, Mukhopadhyay D, et al. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adn Drug Deliv Rev 2010;62:346-61
40. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: Targeted drug delivery for cancer. Curr Opin Chem Biol 2010;14:529-37
41. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 2000;65:271-84 (Pubitemid 30122932
42. Rosenholm JM, Peuhu E, Eriksson JE, et al. Targeted intracellular delivery of hydrophobic agents using mesoporous hybrid silica nanoparticles as carrier systems. Nano Lett 2009;9:3308-11
43. Rosenholm JM, Peuhu E, Bate-Eya LT, et al. Cancer-cell-specific induction of apoptosis using mesoporous silica nanoparticles as drug-delivery vectors. Small 2010;6:1234-41
44. Slowing I, Trewyn BG, Lin VSY. Effect of surface functionalization of MCM-41-Type mesoporous silica nanoparticleson the endocytosis by human cancer cells. J Am Chem Soc 2006;128:14792-3 (Pubitemid 44851603
45. Rosenholm JM, Meinander A, Peuhu E, et al. Targeting of porous hybrid silica nanoparticles to cancer cells. ACS Nano 2009;3:197-206
46. Wu HX, Liu G, Zhang SJ, et al. Biocompatibility, MR imaging and targeted drug delivery of a rattle-Type magnetic mesoporous silica nanosphere system conjugated with PEG and cancer-cell-specific ligands. J Mater Chem 2011;21:3037-45
47. Tsai CP, Chen CY, Hung Y, et al. Monoclonal antibody-functionalized mesoporous silica nanoparticles (MSN) for selective targeting breast cancer cells. J Mater Chem 2009;19:5737-43
48. Zhu CL, Song XY, Zhou WH, et al. An efficient cell-Targeting and intracellular controlled-release drug delivery system based on MSN-PEM-Aptamer conjugates. J Mater Chem 2009;19:7765-70
49. Ma M, Chen HR, Chen Y, et al. Hyaluronic acid-conjugated mesoporous silica nanoparticles: Excellent colloidal dispersity in physiological fluids and targeting efficacy. J Mater Chem 2012;22:5615-21
50. Mal NK, Fujiwara M, Tanaka Y. Photocontrolled reversible release of guest molecules from coumarin-modified mesoporous silica. Nature 2003;421:350-3 (Pubitemid 36157928
51. Vivero-Escoto JL, Slowing II, Wu CW, et al. Photoinduced intracellular controlled release drug delivery in human cells by gold-capped mesoporous silica nanosphere. J Am Chem Soc 2009;131:3462-3
52. Ferris DP, Zhao YL, Khashab NM, et al. Light-operated mechanized nanoparticles. J Am Chem Soc 2009;131:1686-7
53. Lin QN, Huang Q, Li CY, et al. Anticancer drug release from a mesoporous silica based nanophotocage regulated by either a one- or two-photon process. J Am Chem Soc 2010;132:10645-7
54. Liu R, Zhao X, Wu T, et al. Tunable redox-responsive hybrid nanogated ensembles. J Am Chem Soc 2008;130:14418-19
55. Aznar E, Marcos MD, Martinez-Manez R, et al. pH- And photo-switched release of guest molecules from mesoporous silica supports. J Am Chem Soc 2009;131:6833-43
56. Yang Q, Wang SH, Fan PW, et al. pH-responsive carrier system based on carboxylic acid modified mesoporous silica and polyelectrolyte for drug delivery. Chem Mater 2005;17:5999-6003 (Pubitemid 41784404
57. Park C, Oh K, Lee SC, et al. Controlled release of guest molecules from mesoporous silica particles based on a pH-responsive polypseudorotaxane motif. Angew Chem Int Ed 2007;46:1455-7 (Pubitemid 46959995
58. Zhu YF, Shi JL, Shen WH, et al. Stimuli-responsive controlled drug release from a hollow mesoporous silica sphere/ polyelectrolyte multilayer core-shell structure. Angew Chem Int Ed 2005;44:5083-7
59. Lee CH, Cheng SH, Huang IP, et al. Intracellular pH-responsive mesoporous silica nanoparticles for the controlled release of anticancer chemotherapeutics. Angew Chem Int Ed 2010;49:8214-19
60. Kim HJ, Matsuda H, Zhou HS, et al. Ultrasound-Triggered smart drug release from a poly(dimethylsiloxane)-mesoporous silica composite. Adv Mater 2006;18:3083-8 (Pubitemid 46080197
61. Bernardos A, Aznar E, Marcos MD, et al. Enzyme-responsive controlled release using mesoporous silica supports capped with lactose. Angew Chem Int Ed 2009;48:5884-7
62. Bernardos A, Mondragon L, Aznar E, et al Enzyme-responsive intracellular controlled release using nanometric silica mesoporous supports capped with "saccharides". ACS Nano 2010;4:6353-68
63. Coll C, Mondragon L, Martinez-Manez R, et al. Enzyme-mediated controlled release systems by anchoring peptide sequences on mesoporous silica supports. Angew Chem Int Ed 2011;50:2138-40
64. Patel K, Angelos S, Dichtel WR, et al. Enzyme-responsive snap-Top covered silica nanocontainers. J Am Chem Soc 2008;130:2382-3 (Pubitemid 351304722
65. You YZ, Kalebaila KK, Brock SL, et al. Temperature-controlled uptake and release in PNIPAM-modified porous silica nanoparticles. Chem Mater 2008;20:3354-9
66. Liu CY, Guo J, Yang WL, et al. Magnetic mesoporous silica microspheres with thermo-sensitive polymer shell for controlled drug release. J Mater Chem 2009;19:4764-70
67. Schlossbauer A, Kecht J, Bein T. Biotin-Avidin as a protease-responsive cap system for controlled guest release from colloidal mesoporous silica. Angew Chem Int Ed 2009;48:3092-5
68. Climent E, Bernardos A, Martinez-Manez R, et al. Controlled delivery systems using antibody-capped mesoporous nanocontainers. J Am Chem Soc 2009;131:14075-80
69. Zhao YN, Trewyn BG, Slowing II, et al. Mesoporous silica nanoparticle-based double drug delivery system for glucoseresponsive controlled release of insulin and cyclic AMP. J Am Chem Soc 2009;131:8398-9
70. Lee SM, O'Halloran TV, Nguyen ST. Polymer-caged nanobins for synergistic cisplatin-doxorubicin combination chemotherapy. J Am Chem Soc 2010;132:17130-8
71. Kim MH, Na HK, Kim YK, et al. Facile synthesis of monodispersed mesoporous silica nanoparticles with ultralarge pores and their application in gene delivery. ACS Nano 2011;5:3568-76
72. Na HK, Kim MH, Park K, et al. Efficient functional delivery of siRNA using mesoporous silica nanoparticles with ultralarge pores. Small 2012;8:1752-61
73. Chen Y, Chu C, Zhou YC, et al. Reversible pore-structure evolution in hollow silica nanocapsules: Large pores for siRNA delivery and nanoparticle collecting. Small 2011;7:2935-44
74. He QJ, Shi JL, Chen F, et al. An anticancer drug delivery system based on surfactant-Templated mesoporous silica nanoparticles. Biomaterials 2010;31:3335-46
75. He QJ, Gao Y, Zhang LX, et al. A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance. Biomaterials 2011;32:7711-20
76. Chen Y, Gao Y, Chen HR, et al. Engineering inorganic nanoemulsions/ nanoliposomes by fluoride-silica chemistry for efficient delivery/co-delivery of hydrophobic agents. Adv Funct Mater 2012;22:1586-97
77. Lee JE, Lee N, Kim T, et al. Multifunctional mesoporous silica nanocomposite nanoparticles for theranostic applications. Acc Chem Res 2011;44:893-902
78. Arruebo M, Fernandez-Pacheco R, Ibarra MR, Santamaria J. Magnetic nanoparticles for drug delivery. Nano Today 2007;2:22-32 (Pubitemid 46695431
79. Sun C, Lee JSH, Zhang MQ. Magnetic nanoparticles in MR imaging and drug delivery. Adn Drug Deliv Rev 2008;60:1252-65
80. Behrens S. Preparation of functional magnetic nanocomposites and hybrid materials: Recent progress and future directions. Nanoscale 2011;3:877-92
81. Wang Y-XJ. Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application. Quant Imaging Med Surg 2011;1:35-40
82. Kim J, Lee JE, Lee J, et al. Magnetic fluorescent delivery vehicle using uniform mesoporous silica spheres embedded with monodisperse magnetic and semiconductor nanocrystals. J Am Chem Soc 2006;128:688-9 (Pubitemid 43153000
83. Zhao W, Gu J, Zhang L, et al. Fabrication of uniform magnetic nanocomposite spheres with a magnetic core/mesoporous shell structure. J Am Chem Soc 2005;127:8916-17 (Pubitemid 40897560
84. Deng Y, Qi D, Deng C, et al. Superparamagnetic high-magnetization microspheres with an Fe3O4@SiO2 core and perpendicularly aligned mesoporous SiO2 shell for removal of microcystins. J Am Chem Soc 2008;130:28-9
85. Lee JE, Lee N, Kim H, et al. Uniform mesoporous dye-doped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, and drug delivery. J Am Chem Soc 2010;132:552-7
86. Taylor KML, Kim JS, Rieter WJ, et al. Mesoporous silica nanospheres as highly efficient MRI contrast agents. J Am Chem Soc 2008;130:2154-5 (Pubitemid 351287981
87. Viswanathan S, Kovacs Z, Green KN, et al. Alternatives to gadolinium-based metal chelates for magnetic resonance imaging. Chem Rev 2010;110:2960-3018
88. Terreno E, Castelli DD, Viale A, et al. Challenges for molecular magnetic resonance imaging. Chem Rev 2010;110:3019-42
89. Penfield JG, Reilly RF. What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol 2007;3:654-68 (Pubitemid 350146964
90. Tromsdorf UI, Bruns OT, Salmen SC, et al. A highly effective, nontoxic T-1 MR contrast agent based on ultrasmall PEGylated iron oxide nanoparticles. Nano Lett 2009;9:4434-40
91. Perez-Rodriguez J, Lai S, Ehst BD, et al. Nephrogenic systemic fibrosis: Incidence, associations, and effect of risk factor assessment-report of 33 cases. Radiology 2009;250:371-7
92. Kim T, Momin E, Choi J, et al. Mesoporous silica-coated hollow manganese oxide nanoparticles as positive T-1 contrast agents for labeling and MRI tracking of adipose-derived mesenchyrnal stem cells. J Am Chem Soc 2011;133:2955-61
93. Chen Y, Chen H, Zhang S, et al. Structure-property relationships in manganese oxide - mesoporous silica nanoparticles used for T1-weighted MRI and simultaneous anti-cancer drug delivery. Biomaterials 2012;33:2388-98
94. Chen Y, Chen HR, Sun Y, et al. Multifunctional mesoporous composite nanocapsules for highly efficient MRI-guided high-intensity focused ultrasound cancer surgery. Angew Chem Int Ed 2011;50:12505-9
95. Chen Y, Yin Q, Ji XF, et al. Manganese oxide-based multifunctionalized mesoporous silica nanoparticles for pH-responsive MRI, ultrasonography and circumvention of MDR in cancer cells. Biomaterials 2012;33:7126-37
96. Chen Y, Chen HR, Zhang SJ, et al. Structure-property relationships in manganese oxide - nnesoporous silica nanoparticles used for T-1-weighted MRI and simultaneous anti-cancer drug delivery. Biomaterials 2012;33:2388-98
97. Lee CH, Cheng SH, Wang YJ, et al. Near-infrared mesoporous silica nanoparticles for optical imaging: Characterization and in vivo biodistribution. Adv Funct Mater 2009;19:215-22
98. Michalet X, Pinaud FF, Bentolila LA, et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005;307:538-44 (Pubitemid 40165671
99. Pan J, Wan D, Gong JL. PEGylated liposome coated QDs/mesoporous silica core-shell nanoparticles for molecular imaging. Chem Commun 2011;47:3442-4
100. Qian HS, Guo HC, Ho PCL, et al. Mesoporous-silica-coated up-conversion fluorescent nanoparticles for photodynamic therapy. Small 2009;5:2285-90
101. Guo HC, Qian HS, Idris NM, et al. Singlet oxygen-induced apoptosis of cancer cells using upconversion fluorescent nanoparticles as a carrier of photosensitizer. Nanomed-Nanotechnol 2010;6:486-95
102. Liu JA, Bu WB, Zhang SJ, et al. Controlled synthesis of uniform and monodisperse upconversion core/ mesoporous silica shell nanocomposites for bimodal imaging. Chem Eur J 2012;18:2335-41
103. Souris JS, Lee CH, Cheng SH, et al. Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles. Biomaterials 2010;31:5564-74
104. Huang XL, Li LL, Liu TL, et al. The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. ACS Nano 2011;5:5390-9